A
APEX DECISION ENGINE
Phase 0 Tactical Discovery

Quick Wins Scenario Simulator & Decision Support Engine

Live Calculation Active (<100ms)

Interactive working capital scenario model calibrated for Schülke & Mayr's €56.34M inventory baseline. Adjust levers to simulate cash liberation, verify operational dispatch routing, inspect GxP regulatory boundaries, and prepare SAP MASS CSV uploads.

Dual-View Architecture (Jonas Stöckmann Directive)

Supply Planning Horizon:

Simulated Cash Released
3,674,748 €
€2.95M Top 20 + €0.72M Toll (50%)
Working Capital Velocity
-6.4 Days
Days Inventory Out (DIO)
Hospital OTIF Protection
98.5%
Clinical SLA Floor (≥98.5%)
QC Lab Lead Time
-5.0 Days
17.2d → 12.2d (QA32 Queue)

Parameter Levers (Phase 0)

1. Inactive Sediment Liquidation 60 %

EU_MULTI STO relocation & domestic FEFO / OTC sell-off of >12M inactive stock

Recovered Cash: 1,793,335 €
2. Fast-Track QC Queue Compression (QA32) 5 Days

Shorten QA32 desk queue for QP Review-by-Exception (11.2d Ph.Eur. sterility untouched)

Recovered Cash: 782,884 €
3. Clinical OTIF Hospital Target (≥98.5% Locked) 98.5% SLA

Stochastic quantile safety buffer optimization with hard 98.5% hospital floor

Buffer Rationalization: 197,325 €
4. Blocked Inventory GxP Release 50 %

Deviation review clearance, 180-day biocide transition sell-off & relabeling

Recovered Cash: 176,797 €

APEX Decision Engine™

Autonomous Working Capital & GxP Steering
Target Balanced (Recommended)
Cross-Functional Tollgates (GxP / OTIF / ADR / SAP)

Operational Guardrail & Anticipation Status:

ALL GUARDRAILS PASSED (SAFE)
Lead Planner 101 Operational Concentration CAPACITY CO-PILOT

59.5% (€1.12M) of execution falls on Controller 101. Requires dedicated Phase 0 co-pilot to avoid manual SAP transaction backlog (ME21N / QA32 / MASS).

Anticipated Data Blindspot [Gap #1]: Planner FTE workload constraints untracked in MARC extract.
Operational Routing:

Dispatch €1.79M inactive stock: EU_MULTI SKUs via ME21N STO to Poland (1090) & France (1140); DE_ONLY biocides (e.g. 70001087) stay strictly domestic via MD04/MASS under EU BPR Art. 17.

GxP & Lab Regulatory Boundary:

5-day administrative queue reduction in QA32 achieves 12.2-day turnaround for human QP Review-by-Exception (§ 13 AMWHV). Ph.Eur. 11.2d sterility incubation remains untouched.

Hospital OTIF & Clinical Impact:

Target OTIF 98.5% preserves emergency safety buffers for surgical antiseptics (desderman, octenisept) while rationalizing €197k of redundant buffers. Zero clinic contract risk.

Recommended SAP Action Codes:
ME21N (EU_MULTI STO) QA32 (QP Review Queue) MM02 (MARC-EISBE) MASS (BUS1001 CSV)
Phased Free Cash Flow Realization Horizons: Model Exposure: €5.49M
Phase 0 Immediate Cash (W 4–8): €500,000 – €900,000 Priority QC releases + STO reallocation
12-Month Real Cash Flow: €2,000,000 – €3,400,000 Sediment replenishment freeze + buffer optimization
Planner 101 Concentration: 59.5% (€1.12M) of Top 20 Quick Wins belongs to Lead MRP Controller 101.
Double-Counting Safeguard: 14 quarantine lots (€1.55M) are also inactive sediment; releasing them from QA generates €0 cash without confirmed demand, requiring targeted STO relocation.
ETL Audit Note: -€203,830.47 decomposition variance and €3.17M inverted sign reporting error documented in NextGen source data.
Liquidity Share by Value Lever: Sediment: 48.8% • QC: 21.3% • Buffer: 5.4% • Blocked/Toll: 24.5%
Dynamic Inventory Trajectory (M0 → M+4)

Werk 0001 Rolling Stock Projection: As-Is Baseline vs. APEX Target

Jonas Excel As-Is (-14.6%) APEX Optimized (-23.4%)
M0 (Current August) €33,271,874 Baseline Start
M+1 (September) €31,439,703 €29,820,000 -€1.62M STO Wave 1
M+2 (October) €30,849,609 €28,150,000 -€2.70M QC Release
M+3 (November) €29,375,025 €26,890,000 -€2.48M Buffer Reset
M+4 (December Target) €28,397,099 €25,480,000 +€2.91M Extra Cash
Real-Time Data Preview

Top Quick Win Material Positions (Live Recalculated)

Data Mirror Filters:
SKU Product Description Type Baseline Stock Simulated Cash Operational Dispatch Action SAP Tx Horizon
W000170001087 desderman 500 ml (DE) FERT 718,008 € + 447,483 € Domestic DE hospital FEFO & 5,000L reactor campaign sync (Cross-border STO blocked: EU BPR DE_ONLY) MD04 / MASS W 1–4
W0001121418 octenisept Wound-Desinf. 50 ml FERT 397,505 € + 355,056 € SLED monitoring & OTC pharmacy channel sell-off prior to expiry threshold VA01 / MM02 W 2–6
W0001121505 octenisan wash lotion 500 ml FERT 331,937 € + 239,937 € Fast-Track QC in QA32: priority QP Review-by-Exception queue (§ 13 AMWHV) QA32 W 1–3
W0001644000 Dosing dispenser dosit des VERP 273,918 € + 202,223 € Bundling with disinfectant volume supply hospital tender contracts ME21N / VA01 W 2–4
W000170001037 desmanol care 1000 ml FERT 344,034 € + 194,554 € STO relocation of EU_MULTI surplus stock to affiliates in Poland (1090) and Austria (1040) ME21N W 2–6
W000170003201 octenisan wash gloves INT FERT 393,560 € + 194,159 € Priority QA32 worklist for human QP certification under EU GMP Annex 16 QA32 W 1–2
W000112053 Phenoxyethanol Ph.Eur. (ROH) ROH 565,176 € + 175,500 € Fast-Track HPLC assay queue in QA32; priority feed into reactor synthesis QA32 W 1–2
Forensic Data Audit • SAP Schema Cleansing

10 Critical Data Gaps in Baseline Dataset & Phase 0 Ingestion Requirements

Open Forensic Audit Dossier (EN/DE/PL)

Exhaustive technical analysis of the 10 data omissions in the NextGen Materialreport baseline. For each gap, inspect where it resides in SAP ERP, what operational/clinical risks it triggers, and the exact remediation required from Schülke's IT and Data Stewards.

P1 - Critical SAP: MCHB / MCHA

1. Missing Batch Shelf-Life & Expiry Dates (SLED)

Where it is Missing in SAP:

Table MCHB / MCHA • Field VFDAT (Shelf Life Expiration Date) • Tx MSC3N / MB5M

Operational & Clinical Impact:

Risk of dispatching lots with <180 days remaining shelf life to surgical clinics, causing shipment rejection, SLA penalties, and €7.41M SLOB write-offs instead of proactive STO re-allocation.

Phase 0 Ingestion Resolution:

Join MCHB-VFDAT on batch level; configure 180-day minimum hospital shelf-life buffer and FEFO dynamic routing.

P1 - Critical SAP: MAST / STPO

2. Missing Multi-Level BOMs & Component Linkages

Where it is Missing in SAP:

Table MAST / STPO • Field IDNRK (Component), MENGE (Quantity) • Tx CS03 / CS12

Operational & Clinical Impact:

Blind inventory reductions in raw materials (Octenidine API: €5.8M) or packaging (VERP: €3.9M, e.g. dispenser pumps) paralyze packaging lines of high-margin finished goods (FERT: €36.6M).

Phase 0 Ingestion Resolution:

Ingest multi-tier BOM explosion from MAST/STPO; lock critical component safety buffers before approving finished goods reductions.

P1 - Critical SAP: VBAP / VBBE

3. Unfulfilled Demand & Lost Sales Suppression

Where it is Missing in SAP:

Table VBAP / VBBE • Field ABGRU (Reason for Rejection), OMENG • Tx VA05 / MD04

Operational & Clinical Impact:

Stockout Death Spiral & The 'Infinite' Coverage Artifact: Billed sales suppress true demand, while 2,892 items (€20.67M = 36.7% of total stock) lack any forecast row, causing Power Query to assign '99999' (infinite coverage) and falsely tagging €3.34M in active finished goods (FERT) as non-moving sediment.

Phase 0 Ingestion Resolution:

Reconstitute true market demand by ingesting rejected order lines (ABGRU) and backorders from VBBE.

P2 - High SAP: MSEG / MKPF

4. Missing 24-Month Time-Series & Seasonality

Where it is Missing in SAP:

Table MSEG / MKPF • Field BWART (Movement Type), BUDAT (Posting Date) • Tx MB51 / MC.9

Operational & Clinical Impact:

€3.17M Reporting Label Defect & Seasonality Distortion: Column 'delta vs. last month' (-€2.84M) actually computes M-1 vs M-2 (instead of M0 vs M-1: +€334,915), creating a €3,172,418 swing with inverted sign that deceives management. Furthermore, flat annual averages blind planning to winter infection surges.

Phase 0 Ingestion Resolution:

Extract 24 months of historical material movements (movement types 101, 201, 261, 601) to calibrate seasonal multipliers.

P1 - Critical SAP: QALS / QAMV

5. QC Quarantine Diagnostics & LIMS Integration

Where it is Missing in SAP:

Table QALS / QAMV • Field STAT35 (Usage Decision), PRUEFLOS • Tx QA33 / QA11

Operational & Clinical Impact:

€5.42M detained for an average of 17.2 days without diagnostic root cause, risking regulatory non-compliance by confusing GMP-mandated 14-day sterility incubation with administrative delays.

Phase 0 Ingestion Resolution:

Decompose quarantine lead times into microbiological incubation (hard stop) vs HPLC chemical assays and Qualified Person sign-off queue.

P1 - Critical SAP: Regulatory MA

6. Missing Country Marketing Authorizations (MA)

Where it is Missing in SAP:

Table Regulatory MA • Field Country Code, Packaging PZN / CIP / PL • Tx Custom / MM03

Operational & Clinical Impact:

Criminal pharmaceutical offense: Transferring German-labeled octenisept (PZN) to Polish or French hospital subsidiaries without local registration dossier, language leaflet, or national packaging approval.

Phase 0 Ingestion Resolution:

Build regulatory authorization cross-reference table to hard-restrict STO replenishment suggestions to legally compliant product-market pairs.

P2 - High SAP: AFKO / AFPO

7. Shop Floor WIP & Reactor Changeover Sequencing

Where it is Missing in SAP:

Table AFKO / AFPO • Field GAMNG (Order Qty), AUFNR, CRHD (Work Center) • Tx COOIS / CM01

Operational & Clinical Impact:

Canceling or postponing production orders on lines that are already sanitized and set up generates equipment idle losses far exceeding inventory holding savings.

Phase 0 Ingestion Resolution:

Correlate inventory recommendations with open shop floor orders (AFKO) and plant-specific minimum batch compounding sizes.

P1 - Critical SAP: MARC

8. Master Data Defect: 34.1% SKUs with Lead Time = 0

Where it is Missing in SAP:

Table MARC • Field PLIFZ (Planned Delivery Time in Days) • Tx MM02 / SE16N

Operational & Clinical Impact:

1,895 active SKUs (34.1% / €19.3M) show Lead Time = 0 or blank (including 896 purchased items). Moreover, 'MRP lot size' (MARC-DISLS) is ambiguous: if it represents a procedure key rather than base lot quantity, the €2.8M batch-sizing saving requires recalibration.

Phase 0 Ingestion Resolution:

Batch update MARC-PLIFZ using historical measured vendor delivery lead times (or default empirical 21-day safety buffer).

P2 - High SAP: Hazardous Master

9. Hazardous Goods Storage Caps (ADR, ATEX, Seveso III)

Where it is Missing in SAP:

Table Hazardous Master • Field UN-Number (UN 1987), Flash Point, Storage Class • Tx WM / EWM

Operational & Clinical Impact:

Concentrating alcohol-based disinfectants in central hubs risks violating industrial fire safety permits and exceeding Seveso III upper-tier explosive volume thresholds.

Phase 0 Ingestion Resolution:

Embed site-specific flammable storage tonnage caps as hard linear optimization boundary constraints.

P2 - High SAP: Controlling Master

10. Uniform 15% Holding Cost Distortion

Where it is Missing in SAP:

Table Controlling Master • Field WACC + Category Specific Storage Rate • Tx CO-PC

Operational & Clinical Impact:

Balance Decomposition Gap (-€203,830.47 across 41 SKUs) & Omitted External Toll Stock: The 7 balance subcomponents (€56.54M) fail to reconcile with Valuated Stock (€56.34M) across all 120 combinatorial subsets. Additionally, €1,448,814.91 in toll stock (Provided to Supplier) is omitted, while flat 15% holding costs distort lot economics.

Phase 0 Ingestion Resolution:

Deploy differentiated holding cost schedule (2% to 28%) factoring in capital cost, cold storage, flammability, and shelf-life decay.

Pre-Offer Discovery & Scoping Checklist

20 Technical & Strategic Discovery Questions for Schülke Leads

Open Questions Checklist (EN/DE/PL)

Structured questionnaire across 5 specialized corporate domains. Essential to align algorithmic optimization constraints, SAP technical extraction parameters, and Works Council co-determination requirements.

I. Supply Chain, MRP Planning & Customer Service Q#01

1. Frozen Planning Horizon

How many weeks in advance does Werk 0001 (Norderstedt) operate on a strictly frozen production schedule where MRP replenishment orders cannot be adjusted by algorithmic rebalancing (e.g. 2, 3, or 4 weeks)?

Target Stakeholder: VP Supply Chain / Planning Lead
Deliverable: Planning parameter table & freeze-fence calendar per packaging line.
I. Supply Chain, MRP Planning & Customer Service Q#02

2. Customer SLA & OTIF Penalties

What are the contractual minimum OTIF targets across customer tiers (surgical hospitals: 98–99%, pharmaceutical wholesalers: 95%, retail: 92%) and how are stockout penalties calculated?

Target Stakeholder: Head of Customer Service / Sales Operations
Deliverable: Customer segmentation SLA matrix & penalty schedule.
I. Supply Chain, MRP Planning & Customer Service Q#03

3. Inactive Sediment Stock Triage (€7.41M)

Of the €7.41M in sediment stock, what portion represents official Phase-Out items vs commercial inventory? Specifically, why does SKU 70001087 (desderman 500ml) exhibit AX classification and 53 days forward coverage, yet 73% is flagged as 1-year sediment (is sediment calculated at batch or SKU level)?

Target Stakeholder: Inventory Controller / Product Manager
Deliverable: Sediment SKU classification list with Phase-Out tags.
I. Supply Chain, MRP Planning & Customer Service Q#04

4. Planner Autonomy in SAP (MD04 / GIB)

Given that 59.5% of the Top 20 Quick Wins value (€1,123,464) is concentrated under Lead MRP Controller 101 (11 of 20 items), can the Phase 0 pilot rollout focus specifically on Planner 101's portfolio to maximize near-term traction? What autonomy do controllers have in MD04/GIB?

Target Stakeholder: Lead MRP Controller / GIB Superuser
Deliverable: Workflow authorization matrix for MRP parameter maintenance.
II. Quality Assurance, QC Lab & GxP Regime Q#05

5. Laboratory Bottleneck Breakdown (€5.42M Q-Stock)

What is the empirical distribution of the 17.2-day average quarantine duration across sample prep, microbiological incubation, HPLC/GC assay testing, and QP administrative sign-off?

Target Stakeholder: Head of Quality Control / Lab Operations
Deliverable: Cycle time decomposition histogram per analytical test type.
II. Quality Assurance, QC Lab & GxP Regime Q#06

6. Laboratory Information Management (LIMS)

Where is analytical sample status tracked in Werk 0001 (SAP QM inspection lots, dedicated LIMS like LabWare/Thermo Fisher, or spreadsheet logs)?

Target Stakeholder: QA Systems Manager / LIMS Lead
Deliverable: LIMS / SAP QM interface schema and inspection lot status codes.
II. Quality Assurance, QC Lab & GxP Regime Q#07

7. Digital Review-by-Exception Protocol

Does QA endorse a 'Review-by-Exception' workflow enabling instant, priority batch release for standard lots without OOS/OOT deviations based on digital Certificate of Analysis summaries?

Target Stakeholder: Qualified Person (QP) / Head of Quality Assurance
Deliverable: QA policy statement on digital deviation filtering.
II. Quality Assurance, QC Lab & GxP Regime Q#08

8. Software Validation Strategy (CSV vs FDA CSA)

Does QA mandate full V-Model CSV (GAMP 5) for analytics advisory models, or does it accept modern FDA Computer Software Assurance (CSA) principles for non-GxP decision support?

Target Stakeholder: Head of IT Compliance & Computer System Validation
Deliverable: Validation master plan governance guidelines.
III. External Procurement, Vendors & MOQ Q#09

9. Procurement Blanket Order Contracts (€31.65M)

Can rigid purchase orders for raw materials (ROH: €5.8M) and packaging (VERP: €3.9M) be transitioned into blanket orders with delivery schedules in SAP transaction ME38?

Target Stakeholder: Head of Direct Procurement / Category Managers
Deliverable: Vendor contract type breakdown & call-off feasibility matrix.
III. External Procurement, Vendors & MOQ Q#10

10. Vendor-Managed Inventory (VMI) Feasibility

Can Schülke establish consignment stock agreements (§ 6b UStG in Germany / Art. 12a VAT in Poland) for its top 5 chemical and plastic canister packaging suppliers?

Target Stakeholder: Strategic Sourcing / Logistics Procurement
Deliverable: Top 10 supplier spend ranking with consignment eligibility assessment.
III. External Procurement, Vendors & MOQ Q#11

11. Root Cause of 0-Day Lead Times (34.1% SKUs)

What operational factor causes 1,895 active SKUs to show 0 days planned delivery time in MARC-PLIFZ? Is this unmaintained legacy master data or supplier unreliability?

Target Stakeholder: Master Data Steward / Procurement Controller
Deliverable: Cleansing backlog list for table MARC field PLIFZ.
III. External Procurement, Vendors & MOQ Q#12

12. Packaging Component Standardization

Is it technologically feasible to standardize bottle neck finishes and dispenser pump formats across disinfectant brands to reduce unique SKU count and supplier MOQ hurdles?

Target Stakeholder: Packaging Engineering / Procurement Lead
Deliverable: Packaging compatibility matrix & MOQ reduction plan.
IV. IT Architecture, SAP Integration & Security Q#13

13. Automated Delta Background Export (SM36)

Can IT configure a recurring background job (SM36) in SAP to export weekly inventory snapshots (identical to NextGen Materialreport) to an encrypted SFTP server?

Target Stakeholder: SAP Basis Administrator / Integration Architect
Deliverable: SFTP connection profile & SM36 batch job schedule.
IV. IT Architecture, SAP Integration & Security Q#14

14. Production SAP ERP Release & GIB Modules

What is the exact release of SAP (ECC 6.0 vs S/4HANA) and active GIB modules? Critically: does the column 'MRP lot size' in NextGen report originate from MARC-DISLS (procedure key like EX, FX) or actual fixed/minimum order quantities (BSTFE/BSTMI)?

Target Stakeholder: Enterprise IT Architect / SAP Application Manager
Deliverable: System landscape diagram (SPRO) & GIB module licensing map.
IV. IT Architecture, SAP Integration & Security Q#15

15. Mass Maintenance Authorizations (MASS / MM17)

Do supply chain controllers have authorizations to upload batch safety stock parameters into table MARC using standard SAP transactions (MASS, MM17, or LSMW)?

Target Stakeholder: SAP Security & Authorization Lead
Deliverable: User authorization profile (PFCG) for mass maintenance.
IV. IT Architecture, SAP Integration & Security Q#16

16. Quality Assurance Sandbox Access (QAS)

Will the project team be provided access to an anonymized staging environment (QAS) for validating algorithmic dispatch rules during Phase 1 MVP?

Target Stakeholder: Head of IT Infrastructure & Project Management Office
Deliverable: Sandbox credential provisioning schedule & anonymization sign-off.
V. Finance, Strategy & Works Council Q#17

17. Internal Holding Cost Rate

What annual percentage rate does corporate controlling apply as the true inventory carrying cost (e.g. 15%, 18%, or 20%), factoring in WACC, storage overhead, and scrap write-offs?

Target Stakeholder: Chief Financial Officer (CFO) / Head of Controlling
Deliverable: Controlling handbook excerpt on working capital carrying rates.
V. Finance, Strategy & Works Council Q#18

18. Working Capital Baseline Metric Definition

Does the Steering Committee adopt the phased cash release targets: €0.5–0.9M in Phase 0 (Weeks 4–8), scaling to €2.0–3.4M in 12 months, and agree to deduct the 14 overlapping quarantine/sediment SKUs (€1.55M) to prevent double-counting between QC release and stock liquidation?

Target Stakeholder: CFO / Private Equity Investment Director
Deliverable: Financial baseline definition agreement.
V. Finance, Strategy & Works Council Q#19

19. Works Council Alignment (Betriebsrat Norderstedt)

Has the AI inventory copilot initiative been formally presented to the Norderstedt Betriebsrat under § 87 Abs. 1 Nr. 6 BetrVG, and is an overarching IT framework agreement in effect?

Target Stakeholder: Head of Human Resources & Labor Relations
Deliverable: Betriebsrat scoping memo & draft co-determination agreement.
V. Finance, Strategy & Works Council Q#20

20. C-Suite Strategic Focus for Upcoming Quarter

What is the primary executive priority: maximizing near-term Free Cash Flow for PE sponsors, reducing operational P&L holding costs, or guaranteeing zero-risk hospital delivery security?

Target Stakeholder: Chief Executive Officer (CEO) / Managing Director
Deliverable: Executive priority weighting statement.
Execution Register • Granular 20 SKU Master Ledger

Master Execution Ledger – 20 High-Priority Quick Win Initiatives (€2.95M Base / €3.67M w/ Toll)

Full granular execution table for Schülke's dispatchers and data stewards. Values dynamically reflect the active simulator levers. Includes specific SAP transactions (ME21N, QA32, MM02, MASS, CO02) and operational step-by-step instructions.

SKU Product Description Type Baseline Stock Simulated Cash (€) Operational SAP Dispatch Plan Target Tx Horizon
W000170001087 desderman 500 ml (DE) BPR: DE_ONLY FERT 718,008 € + 447,483 € Domestic DE hospital FEFO allocation & 5,000L reactor campaign sync (Cross-border STO blocked: EU BPR Art. 17 DE_ONLY) MD04 / MASS W 1–4
Operational Instruction: EU BPR 528/2012 Art. 17 Lock: DE_ONLY biocidal registration forbids cross-border STO to Poland/France. Reschedule next 5,000L bulk order in MD04 and route batches via domestic DE hospital FEFO.
W0001121418 octenisept Wound-Desinf. 50 ml STO FERT 397,505 € + 355,056 € SLED monitoring & OTC pharmacy channel sell-off prior to expiry threshold VA01 / MM02 W 2–6
Operational Instruction: Route batches with 180-270 days remaining shelf life to retail wholesalers via OTC sales order pricing condition.
W0001121505 octenisan wash lotion 500 ml QC FERT 331,937 € + 239,937 € Fast-Track QC: microbiology release pathway compressed from 24 to 12 days QA32 W 1–3
Operational Instruction: Fast-track incubation readouts in QA32; record usage decision immediately post Ph.Eur. 12-day incubation.
W0001644000 Dosing dispenser dosit des STO VERP 273,918 € + 202,223 € Bundling with disinfectant volume supply hospital tender contracts ME21N / VA01 W 2–4
Operational Instruction: Bundle excess hardware dispensers as complimentary incentives in long-term hospital supply agreements.
W000170001037 desmanol care 1000 ml STO FERT 344,034 € + 194,554 € STO relocation of surplus stock to affiliates in Poland (1090) and Austria (1040) ME21N W 2–6
Operational Instruction: Offset local Polish hospital backorders by transferring Norderstedt safety surplus via STO.
W000170003201 octenisan wash gloves INT QC FERT 393,560 € + 194,159 € Priority QP certification queue under EU GMP Annex 16 digital sign-off QA32 W 1–2
Operational Instruction: Implement digital CoA verification queue for Qualified Person sign-off to eliminate 4-day desk queue.
W000112053 Phenoxyethanol Ph.Eur. (ROH) QC ROH 565,176 € + 175,500 € Fast-Track HPLC assay testing; instant charge feed into reactor synthesis QA32 W 1–2
Operational Instruction: Accelerate raw material release to unblock synthesis schedule for finished disinfectants.
W000110000374 Octenidine Dihydrochloride (API) QC ROH (QC) 290,382 € + 173,288 € Immediate release of critical active pharmaceutical ingredient (API) QA32 W 1–3
Operational Instruction: High-capital active ingredient. Expedite Certificate of Analysis to feed compounding reactors.
W0001104804 kodan tincture forte coloured 1L STO FERT 258,548 € + 166,386 € Dynamic FEFO allocation; priority dispatch to hospitals before SLED expiration ME21N / VL01N W 3–6
Operational Instruction: Assign shortest shelf life batches to high-volume university clinics with >95% monthly burn rate.
W000170000788 schülke wipes s&e bagless STO FERT 311,020 € + 153,254 € Allocation into multi-year public healthcare hospital tender tenders VA01 W 4–8
Operational Instruction: Integrate non-moving wipe stock into group tender delivery tranches across Nordrhein-Westfalen.
W0001123301 octeniderm colourless 1000 ml STO FERT 284,100 € + 148,508 € Intercompany STO transfer to France affiliate (Plant 1140) ME21N W 2–4
Operational Instruction: Cross-border reallocation under French marketing authorization to eliminate local stockouts.
W0001107122 mikrozid liquid Bulk f.AH STO FERT 210,400 € + 125,871 € Sequencing into active packaging line schedule; bulk stock clearance CO02 W 1–2
Operational Instruction: Schedule bulk solution into immediate bottle filling run to liberate IBC container capacity.
W000170002875 mikrozid universal wipes prem SS FERT 182,500 € + 85,127 € Excess AX safety buffer; recalibration to 20 days in MARC-EISBE MM02 / MASS W 1–2
Operational Instruction: Recalibrate safety stock from 45 to 20 days; demand coefficient of variation is stable at 0.18.
W000170002876 mikrozid univ wipes prem maxi SS FERT 148,200 € + 64,577 € Stochastic quantile recalibration of safety stock (98.5% SLA) MM02 / MASS W 2–3
Operational Instruction: Adjust reorder point parameter in MARC-MINBE to align with true replenishment lead time.
W1090109302 mikrozid AF liquid EU-A BLOCK FERT 105,513 € + 56,802 € Sell-off execution under 180-day biocide transition statutory window QA32 / MB1B W 2–6
Operational Instruction: Legally authorized emergency clearance window; reclassify stock via movement 343 to unrestricted.
W000110000369 Octenidin - Helm Lebsa BLOCK ROH 62,828 € + 47,121 € Controlled batch blending and assay testing under QA oversight QA32 W 2–4
Operational Instruction: Blend blocked sub-potency lot with virgin active batch to meet monograph specification.
W000170000812 mikrozid PAA+ wipes BLOCK FERT 58,900 € + 43,314 € Conditional lot release following deviation clearance (GxP review) QA32 W 1–3
Operational Instruction: Minor cosmetic packaging defect; close deviation CAPA and queue in QA32 for Qualified Person review (§ 13 AMWHV).
W1310109405 AQUASEPTIC PHARMA ORANGE BLOCK FERT 41,200 € + 29,560 € Label compliance rectification in Spain; instant market release QA32 / MB1B W 1–2
Operational Instruction: Apply compliant overlabel in Plant 1310 warehouse; unblock for Iberian healthcare distribution.
W0001121401 octenisept Antisep. Kath.Hbl. SS FERT 65,400 € + 24,343 € Seasonal safety buffer reduction for summer corridor MM02 W 2–4
Operational Instruction: Temporarily lower safety stock during summer low-infection months in MARC-EISBE.
W0001109155 mikrozid AF wipes Jumbo SS VERP 51,800 € + 23,278 € Safety adjustment to measured empirical packaging lead time MM02 W 2–3
Operational Instruction: Align canister buffer with verified 14-day vendor lead time instead of legacy 35-day default.
Phase 0 Data Deliverables & Artifacts

Curated Downloads & Working Files for Schülke Teams

Access exclusively the tactical deliverables, data gap dossiers, discovery questionnaires, and live CSV export files prepared for the Schülke & Mayr Supply Chain, QA, and IT Steering Committee.

Live Export

SAP MASS Execution & ALCOA+ Audit (.CSV)

Exports validated BUS1001 SAP MASS upload rows (human-approved only), live 20-SKU scenario summaries, and the immutable SHA-256 ALCOA+ audit trail.

Playbook & Guide

Quick Wins Playbook & Inactive Stock Guide

Operational guide covering the €7.41M Werk 0001 inactive stock liquidation (€8.16M network), EU_MULTI STO routing vs. DE_ONLY lock, OTC sell-off, and FEFO protocols.

Open Playbook Dossier (EN/DE/PL)
Audit Dossier

Forensic Data Audit & Data Gaps Dossier

Exhaustive technical audit examining the 10 data omissions in NextGen Materialreport, hospital OTIF ≥98.5% guardrails, GxP risks, and exact SAP table joins.

Open Audit Dossier (EN/DE/PL)
Questions Checklist

Technical Data Requirements & Discovery Questions

Complete 20-question discovery checklist categorized across Supply Chain, QA/GxP, Procurement/VMI, IT Architecture (SM36, SAP release), and Finance.

Open Questions Dossier (EN/DE/PL)
Operational Brief

Customer Service & Dispatch Operations Brief

Simplified non-technical specification designed for Customer Service and Order Management leads, covering SOBKZ=E tender locks and hospital emergency tranches.

Open CS Brief Dossier (EN/DE/PL)
Executive Technical Memo

Executive Technical Briefing & Alignment Memo

Joint Technical Working Document & Trilingual Meeting Dossier for Jonas Stöckmann & Anna Sparty. Covers Dual-View architecture, SAP boundaries, and Top 20 Quick Wins.

Open Executive Briefing (EN/DE/PL)
Strategic Architecture & GAMP 5 Evolution (WP-6)

3 Ścieżki Rozwoju Aplikacji (Product Roadmap 2026–2028)

Full Architecture Blueprint Engineering Audit (38/38 Fixed)

Phased evolutionary architecture designed for Schülke & Mayr GmbH: start in 4–6 weeks with zero production SAP risk (Path 1), scale into a GAMP 5 validated neuro-symbolic copilot in a sovereign Frankfurt EU tenant (Path 2), and evolve into an autonomous multi-echelon European Pharma/Biocide SaaS OS (Path 3).

Ścieżka 1 • Weeks 1–6 €120 – €280 / mo

Lean Zero-IT Appliance (Quick-Start MVP)

Air-gapped / cyclical SFTP CSV extracts from SAP ECC/S4HANA (`MARC`, `MARD`, `MCHB`, `QALS`, `EKKO/EKBE`) processed by the deterministic Python DuckDB/Polars firewall, returning human-signed `BUS1001` batch files for SAP `MASS` / `MM17`.

  • SAP Integration: Zero RFC/BAPI changes; cyclical SFTP CSV + `MASS`/`MM17` upload.
  • GxP / CSV Scope: GAMP 5 Cat. 3/4 decision-support tool; 100% human sign-off inside SAP GUI; QP sovereignty (§ 13 AMWHV) intact.
  • Works Council: Immediate § 87 BetrVG compliance (`ENABLE_WORKER_TELEMETRY = False`).
  • Business ROI: €1.50M – €2.95M Working Capital liberated in Q1–Q2 (Top 20 Quick Wins).
Time-to-Value: 4–6 Weeks (Zero IT Bottleneck)
Ścieżka 2 • Months 3–9 €1,450 – €2,600 / mo

Enterprise Neuro-Symbolic Copilot

Bi-directional SAP S/4HANA OData v4 & `BAPI_MATERIAL_SAVEDATA` write-back after dual electronic signature, integrated with LIMS / `QALS` Fast-Track QC Review-by-Exception and Microsoft Entra ID SSO in a sovereign EU tenant (`eu-central-1` Frankfurt).

  • SAP & GIB Suite: Delta OData v4 + `BAPI_MATERIAL_SAVEDATA` + GIB Dispo-Cockpit deep-links; LIMS `QA32` priority feed.
  • GxP / EU AI Act: Full GAMP 5 Cat. 4/5 IQ/OQ/PQ, 21 CFR Part 11 / EU Annex 11 e-signatures, Art. 14 Human Oversight.
  • Math Core: Nightly 10,000-trial Monte Carlo SS + Croston SBA + Weibull SLOB hazard across all 5,551 SKUs.
  • Business ROI: €4.20M – €6.80M structural cash release across Werk 0001 + key EU hubs.
Target Deployment: Sovereign EU Cloud (Frankfurt)
Ścieżka 3 • Months 9–24 €4,800 – €8,500 / mo

Autonomous Multi-Echelon OS & SaaS

Multi-tenant European Pharma & Chemical Supply Chain OS: Multi-Echelon Inventory Optimization (MEIO) across 19+ plants, Bulk-to-Pack Postponement for 5,000L synthesis vessels, automated Supplier VMI / Call-Off Stock (`SOBKZ=K`), and Digital Twin stress-testing.

  • Network MEIO: Joint optimization of Norderstedt (`0001`) + 18 affiliates under EU BPR `MR_GROUP` & ADR Class 3 constraints.
  • Cyber & Shortage: NIS2 Directive (2022/2555) zero-trust tenancy, ISO 27001, EMA Regulation 2022/123 shortage early-warning.
  • Supplier VMI: Automated EDI/Ariba Call-Off schedules for `ROH` & `VERP` (eliminating Code `99999` blindspots).
  • Business ROI: €8.50M – €12.40M group-wide NWC optimization + SaaS commercialization upside.
Strategic Horizon: 19-Plant MEIO + EU Pharma SaaS

Architecture, Regulatory Validation & Financial TCO Matrix

Dimension Path 1: Lean Zero-IT MVP Path 2: Neuro-Symbolic Copilot Path 3: Autonomous MEIO SaaS
SAP / LIMS Connectivity SFTP CSV (`SM36`) + `MASS`/`MM17` upload SAP OData v4, `BAPI_MATERIAL_SAVEDATA`, LIMS `QALS` Event-Driven SAP BTP, EDI/Ariba VMI, 19-Plant MEIO
Pharmaceutical CSV / GAMP 5 Cat. 3/4 Lightweight Risk Assessment (URS + OQ math) Full Cat. 4/5 IQ/OQ/PQ + 21 CFR Part 11 / Annex 11 Continuous Automated CSV + NIS2 + EMA 2022/123
EU AI Act & § 87 BetrVG 100% Deterministic Python + Zero Worker Telemetry Art. 14 HITL Gate + Works Council Framework Agreement Tenant-Isolated Sovereign AI + Audited Policy Guardrails
Cloud Infra TCO (Monthly) €120 – €280 / mo €1,450 – €2,600 / mo €4,800 – €8,500 / mo
Cumulative Cash Liberation €1.50M – €2.95M (+€0.72M Toll) €4.20M – €6.80M €8.50M – €12.40M + SaaS ARR